Immunosuppression of Syrian golden hamsters accelerates relapse but not the emergence of resistance in Leishmania infantum following recurrent miltefosine pressure

Although miltefosine (MIL) has only been approved for the treatment of visceral leishmaniasis (VL) in 2002, its application in monotherapy already led to the development of two confirmed MIL-resistant isolates by 2009. Although liposomal amphotericin B is recommended as first-line treatment in Europ...

Descripción completa

Detalles Bibliográficos
Autores principales: Hendrickx, S., Bulté, D., Van den Kerkhof, M., Cos, P., Delputte, P., Maes, L., Caljon, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296292/
https://www.ncbi.nlm.nih.gov/pubmed/30562667
http://dx.doi.org/10.1016/j.ijpddr.2018.12.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296292/
https://www.ncbi.nlm.nih.gov/pubmed/30562667
http://dx.doi.org/10.1016/j.ijpddr.2018.12.001

Ejemplares similares